Actuate Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard
Nasdaq notified Actuate Therapeutics that its stock closed below $1.00 for 30 days, violating listing rules. The company has until April 26, 2027, to comply. It also faces a market value deficiency deadline of January 11, 2027. Trading is unaffected.
How this was made

The 30-second read
Why it matters
The filing signals a compliance risk that could lead to delisting if not remedied by the April 26, 2027 deadline, likely prompting short‑term sell pressure.
Market read
A primary disclosure of a delisting notice for a micro‑cap biotech, creating immediate compliance risk and potential price downside.
What to watch
Potential for a reverse split or a strategic partnership that could restore compliance without a large cash infusion.
Background
Actuate Therapeutics (ACTU) received a Nasdaq Listing Rule 5450(a)(1) notice for trading below the $1 minimum bid price for 30 consecutive business days and a market‑value deficiency.
Ticker impact
Nasdaq notified Actuate Therapeutics that its share price fell below $1 for 30 days, triggering a delisting compliance notice.
likely downward pressure as investors price in potential delisting risk
Compliance failures on low‑price listings historically lead to share sell‑offs until the company regains $1 price or raises capital.
Market effects
May raise scrutiny on other micro‑cap biotech stocks hovering near $1 listing thresholds.
Limited to U.S. Nasdaq micro‑cap segment; no broader regional effect.
Minimal global impact; primarily a company‑specific compliance issue.
Counterpoint
If Actuate can secure a capital raise quickly, the delisting risk may be short‑lived and present a buying opportunity at depressed prices.
Key entities
- CompanyActuate Therapeutics, Inc.
Biotech firm listed on Nasdaq under ticker ACTU.
- RegulatorNasdaq
Exchange that issued the compliance notice.
